Karyopharm to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company specializing in novel cancer therapies, has announced its participation in two upcoming investor conferences in September 2024:

• H.C. Wainwright 26th Annual Global Investment Conference on September 10, featuring a podium presentation at 9:00 a.m. ET
• Baird 2024 Global Healthcare Conference on September 11, with a fireside chat at 10:50 a.m. ET

Live webcasts and slides will be available on the company's website. Karyopharm is known for its oral compound XPOVIO® (selinexor), an XPO1 inhibitor approved in the U.S. for three oncology indications and in other countries as NEXPOVIO®. The company focuses on high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL.

NEWTON, Mass., Sept. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:

H.C. Wainwright 26^th Annual Global Investment Conference
Format: Podium presentation
Date: Tuesday, September 10, 2024
Time: 9:00 a.m. ET

Baird 2024 Global Healthcare Conference
Format: Fireside chat
Date: Wednesday, September 11, 2024
Time: 10:50 a.m. ET

A live webcast of these events, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-upcoming-investor-conferences-302235059.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When is Karyopharm Therapeutics (KPTI) participating in the H.C. Wainwright Global Investment Conference?

Karyopharm Therapeutics (KPTI) is participating in the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, with a podium presentation at 9:00 a.m. ET.

What type of presentation will Karyopharm (KPTI) give at the Baird 2024 Global Healthcare Conference?

Karyopharm (KPTI) will participate in a fireside chat at the Baird 2024 Global Healthcare Conference on Wednesday, September 11, 2024, at 10:50 a.m. ET.

Where can investors access the webcasts of Karyopharm's (KPTI) conference presentations?

Investors can access live webcasts of Karyopharm's (KPTI) conference presentations under the 'Events & Presentations' section in the Investor area of the company's website at http://investors.karyopharm.com/events-presentations.

What is Karyopharm Therapeutics' (KPTI) lead compound?

Karyopharm Therapeutics' (KPTI) lead compound is XPOVIO® (selinexor), a first-in-class, oral exportin 1 (XPO1) inhibitor approved in the U.S. for three oncology indications.

What cancer types does Karyopharm Therapeutics (KPTI) focus on in its pipeline?

Karyopharm Therapeutics (KPTI) focuses on high unmet need cancers in its pipeline, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).